GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Net Margin %

Atara Biotherapeutics (Atara Biotherapeutics) Net Margin % : -1,421.68% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Atara Biotherapeutics's Net Income for the three months ended in Dec. 2023 was $-60.45 Mil. Atara Biotherapeutics's Revenue for the three months ended in Dec. 2023 was $4.25 Mil. Therefore, Atara Biotherapeutics's net margin for the quarter that ended in Dec. 2023 was -1,421.68%.

The historical rank and industry rank for Atara Biotherapeutics's Net Margin % or its related term are showing as below:

ATRA' s Net Margin % Range Over the Past 10 Years
Min: -3220.88   Med: -1672.28   Max: -359.12
Current: -3220.88


ATRA's Net Margin % is ranked worse than
83.45% of 1027 companies
in the Biotechnology industry
Industry Median: -162.84 vs ATRA: -3220.88

Atara Biotherapeutics Net Margin % Historical Data

The historical data trend for Atara Biotherapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Net Margin % Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -1,672.28 -359.12 -3,220.88

Atara Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33,742.99 -6,098.78 -7,430.30 -3,264.59 -1,421.68

Competitive Comparison of Atara Biotherapeutics's Net Margin %

For the Biotechnology subindustry, Atara Biotherapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Net Margin % falls into.



Atara Biotherapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Atara Biotherapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-276.126/8.573
=-3,220.88 %

Atara Biotherapeutics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-60.45/4.252
=-1,421.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atara Biotherapeutics  (NAS:ATRA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Atara Biotherapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (Atara Biotherapeutics) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Executives
Jill Henrich officer: EVP, Global Head RA & Quality 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Pascal Touchon director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080
Amar Murugan officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080
Eric J Hyllengren officer: SVP, CFO 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Anhco Nguyen officer: EVP, Chief Sci. & Tech Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Manher Joshi officer: EVP, Chief Medical Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Eric Dobmeier director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Charlene A. Banard officer: EVP, Chief Technical Officer C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
Jakob Dupont officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Utpal Koppikar officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Ameet Mallik director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Kristin Yarema officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Joe Newell officer: Chief Tech. Operations Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080